Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optcal biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced that its UroFlex™ confocal miniprobe received CE mark approval for use during cystoscopy procedures. UroFlex is the frst optcal biopsy probe designed for urological applicatons and allows the company to enter the €1 billion European urology device market.i The new probe allows physicians to obtain optcal biopsies that may facilitate the diagnosis, surveillance and treatment of patents with bladder cancer.
“Bladder cancer has a very high recurrence rate, and because it requires life-long surveillance and multple repeat cystoscopy procedures, it is one of the most expensive cancers to treat on a per patent basis,” said Maurizio Brausi, MD, Professor and Chairman of Urology, AUSL Modena, Italy and chairman of the EAU Secton of Oncological Urology. “With optcal biopsies, physicians have an immediate view of cells within the bladder and ureter, which gives us a whole new set of data allowing more informed treatment decisions. This could allow us to more efectvely determine if we have removed all the cancerous cells during minimally invasive surgery to reduce repeat surgeries for the patent.”